Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy

NCT02129699 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

595

Enrollment

NETWORK

Sponsor class

Stopped Completion of recruitment was not feasible as accrual was slower than anticipated. Even if a benefit for denosumab could be shown, these results would be of very limited clinical impact by the time they would be available

Conditions

Lung Cancer Non-small Cell Stage IV

Interventions

DRUG: Denosumab
OTHER: None, standard chemotherapy only

Sponsor

ETOP IBCSG Partners Foundation

Collaborators

[object Object]
[object Object]